<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00153803</url>
  </required_header>
  <id_info>
    <org_study_id>D-0410</org_study_id>
    <nct_id>NCT00153803</nct_id>
  </id_info>
  <brief_title>Erlotinib or Placebo Following Chemoradiotherapy (Chemo/RT) in Stage III Non-Small Cell Lung Cancer (NSCLC)</brief_title>
  <official_title>A National Web-Based Randomized Phase III Study of Erlotinib or Placebo Following Concurrent Docetaxel, Carboplatin, and Thoracic Radiotherapy in Patients With Inoperable Stage III Non-Small Cell Lung Cancer (D0410).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dartmouth-Hitchcock Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Dartmouth-Hitchcock Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a national, randomized, web-based, double-blind study to determine whether erlotinib
      (Tarceva) compared to placebo improves progression-free survival (PFS) for patients with
      inoperable, stage III NSCLC following concurrent docetaxel, carboplatin and thoracic
      radiotherapy. We hypothesize that the introduction of this orally active, well-tolerated
      agent following concurrent chemoradiation and prior to the emergence of drug resistance will
      prolong the progression-free survival by 40% (10 months â†’ 14 months).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The promising activity of erlotinib as a single agent in advanced refractory NSCLC along with
      its oral administration and favorable adverse event profile makes this agent an excellent
      candidate to incorporate into combined modality therapy in the early stages of lung cancer.
      Based on these data, erlotinib is an attractive novel approach to maintenance therapy in
      unresectable stage III NSCLC following completion of concomitant chemoradiation. Although, a
      subset of patients with unresectable stage III NSCLC will be long-term survivors following
      chemotherapy and thoracic radiation therapy, the vast majority relapse within the first year
      following therapy and eventually die from chemotherapy refractory disease. We hypothesize
      that the introduction of an potent tyrosine kinase inhibitor to the epidermal growth factor
      receptor following effective concomitant chemoradiotherapy with docetaxel and carboplatin
      will prolong the progression-free survival time for these patients.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2005</start_date>
  <completion_date type="Actual">April 2014</completion_date>
  <primary_completion_date type="Actual">April 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>5 years</time_frame>
    <description>Progression Free Survival is defined as time from randomization until documented disease progression or death from any cause. The Response Evaluation Criteria In Solid Tumors Criteria (RECIST 1.0) was used to determine disease progression. Irradiated target lesions were considered non-measurable disease. Symptomatic radiographic changes of irradiated non-measurable disease required pathologically confirmation or positive FDG-PET scan 6 months following completion of concurrent chemoradiation to be considered locoregional disease progression. Global deterioration of health status requiring discontinuation of treatment without objective evidence of progression was considered distant disease progression.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>From date of randomization until the date of death from any cause, assessed up to 50 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of Participants Surviving 3 Years</measure>
    <time_frame>36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serious Adverse Event Profile Relating to Death, Disability, Life-threatening, Hospitalization, and Impairment/Damage for Concurrent Chemoradiation</measure>
    <time_frame>18 months</time_frame>
    <description>Number of participants with treatment-related serious adverse events (SAEs) observed in each SAE category for each arm relating to death, disability, life-threatening, hospitalization, and impairment/damage is reported. For participants with multiple SAEs, the SAE report having the strongest relationship to study drug is summarized.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serious Adverse Event Profile Relating to Death, Disability, Life-threatening, Hospitalization, and Impairment/Damage for Erlotinib and Placebo</measure>
    <time_frame>18 months</time_frame>
    <description>Number of participants with treatment-related serious adverse events (SAEs) observed in each SAE category for each arm relating to death, disability, life-threatening, hospitalization, and impairment/damage is reported. For participants with multiple SAEs, the SAE report having the strongest relationship to study drug is summarized.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">245</enrollment>
  <condition>Carcinoma, Non-Small-Cell Lung</condition>
  <condition>Non-small Cell Lung Cancer</condition>
  <condition>NSCLC</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Erlotinib (Tarceva) 150mg: Erlotinib 150mg orally each day. Patients will be treated on a continuous, once daily oral dosing schedule until disease progression, withdrawal of consent, unacceptable adverse events, death or completion of 3 years of therapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matched Placebo: Matched placebo orally each day. Patients will be treated on a continuous, once daily oral dosing schedule until disease progression, withdrawal of consent, unacceptable adverse events death or completion of 3 years of therapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Erlotinib (tarceva)</intervention_name>
    <description>Erlotinib 150mg orally each day. Patients will be treated on a continuous, once daily oral dosing schedule until disease progression, withdrawal of consent, unacceptable adverse events, death or completion of 3 years of therapy.</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matched placebo orally each day. Patients will be treated on a continuous, once daily oral dosing schedule until disease progression, withdrawal of consent, unacceptable adverse events death or completion of 3 years of therapy.</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Unresectable, stage IIIA or IIIB NSCLC (measurable disease is not required)

          -  No evidence of metastatic disease

          -  No prior treatment

          -  Adequate organ function

          -  Adequate pulmonary function (FEV &gt;= 1.0L or predicted FEV &gt;0.8L)

        Exclusion Criteria:

          -  Metastasis

          -  Prior treatment

          -  Malignant pleural or pericardial effusion

          -  Peripheral neuropathy &gt;= grade 2
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James R Rigas, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Norris Cotton Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Birmingham Hematology and Oncology Associates, LLC</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35235</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oncology Specialties, P.C.</name>
      <address>
        <city>Huntsville</city>
        <state>Alabama</state>
        <zip>35801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cooper Clinic</name>
      <address>
        <city>Fort Smith</city>
        <state>Arkansas</state>
        <zip>72913</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Genesis Cancer Center</name>
      <address>
        <city>Hot Springs</city>
        <state>Arkansas</state>
        <zip>71913</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alta Bates Comprehensive Cancer Center</name>
      <address>
        <city>Berkeley</city>
        <state>California</state>
        <zip>94704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northstate Cancer Speciality</name>
      <address>
        <city>Redding</city>
        <state>California</state>
        <zip>96001</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mercy General Hospital</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95816</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Francis Hospital Cancer Center</name>
      <address>
        <city>Hartford</city>
        <state>Connecticut</state>
        <zip>06105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Connecticut Oncology Group</name>
      <address>
        <city>Middletown</city>
        <state>Connecticut</state>
        <zip>06457</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>George Bray Cancer Center/New Britain General Hospital</name>
      <address>
        <city>New Britain</city>
        <state>Connecticut</state>
        <zip>06050</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oncology and Hematology Associates, PC</name>
      <address>
        <city>New London</city>
        <state>Connecticut</state>
        <zip>06320</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Whittingham Cancer Center at Norwalk Hospital</name>
      <address>
        <city>Norwalk</city>
        <state>Connecticut</state>
        <zip>06856</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hematology/Oncology PC/Carl and Dorothy Bennet Cancer Center</name>
      <address>
        <city>Stamford</city>
        <state>Connecticut</state>
        <zip>06902</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington Cancer Institute</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pasco Hernando Oncology Associates</name>
      <address>
        <city>Brooksville</city>
        <state>Florida</state>
        <zip>34613</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Cancer Specialists</name>
      <address>
        <city>Fort Myers</city>
        <state>Florida</state>
        <zip>33901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lee Cancer Clinic</name>
      <address>
        <city>Fort Myers</city>
        <state>Florida</state>
        <zip>33919</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jupiter Medical Center</name>
      <address>
        <city>Jupiter</city>
        <state>Florida</state>
        <zip>33458</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Care of North Florida</name>
      <address>
        <city>Lake City</city>
        <state>Florida</state>
        <zip>32055</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pasco/Hernando Oncology</name>
      <address>
        <city>New Port Richey</city>
        <state>Florida</state>
        <zip>34652</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mid Florida Oncology</name>
      <address>
        <city>Orange City</city>
        <state>Florida</state>
        <zip>32763</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MD Anderson</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oncology &amp; Hematology Association of West Broward</name>
      <address>
        <city>Tamarac</city>
        <state>Florida</state>
        <zip>33321</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Palm Beach Cancer Institute</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33410</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alexian Brothers Hospital Network</name>
      <address>
        <city>Elk Grove Village</city>
        <state>Illinois</state>
        <zip>60007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Joliet Hematology Associates</name>
      <address>
        <city>Joliet</city>
        <state>Illinois</state>
        <zip>60435</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative Clinical Research of Indiana LLC</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46254</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Howard Regional Health System</name>
      <address>
        <city>Kokomo</city>
        <state>Indiana</state>
        <zip>46904</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>McFarland Clinic</name>
      <address>
        <city>Ames</city>
        <state>Iowa</state>
        <zip>50010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kentucky Cancer Clinic</name>
      <address>
        <city>Hazard</city>
        <state>Kentucky</state>
        <zip>41701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Western Hematology Oncology</name>
      <address>
        <city>Paducah</city>
        <state>Kentucky</state>
        <zip>42003</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maine Center for Cancer Medicine</name>
      <address>
        <city>Scarborough</city>
        <state>Maine</state>
        <zip>04074</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sinai Hospital of Baltimore</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Union Memorial Hospital</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21218</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Harbor View Cancer Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21225</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Franklin Square Hospital Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21237</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Frederick Smith, MD</name>
      <address>
        <city>Chevy Chase</city>
        <state>Maryland</state>
        <zip>20815</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Community Hematology Oncology</name>
      <address>
        <city>Olney</city>
        <state>Maryland</state>
        <zip>20832</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lahey Clinic Medical Center</name>
      <address>
        <city>Burlington</city>
        <state>Massachusetts</state>
        <zip>01805</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fallon Clinic Hematology/ Oncology</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>01608</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bay Medical Cancer Center</name>
      <address>
        <city>Bay City</city>
        <state>Michigan</state>
        <zip>48706</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southeast Nebraska Hematology/Oncology</name>
      <address>
        <city>Lincoln</city>
        <state>Nebraska</state>
        <zip>68510</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Methodist Cancer Center</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nevada Cancer Research Foundation</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dartmouth-Hitchcock-Keene</name>
      <address>
        <city>Keene</city>
        <state>New Hampshire</state>
        <zip>03431</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Norris Cotton Cancer Center</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <zip>03756</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Center for Cancer and Hematologic Disease</name>
      <address>
        <city>Cherry Hill</city>
        <state>New Jersey</state>
        <zip>00000</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sussex County Medical Associates</name>
      <address>
        <city>Newton</city>
        <state>New Jersey</state>
        <zip>07860</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lincoln Hospital</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10451</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Queens Medical Associates</name>
      <address>
        <city>Fresh Meadows</city>
        <state>New York</state>
        <zip>11365</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Winthrop University Hospital</name>
      <address>
        <city>Mineola</city>
        <state>New York</state>
        <zip>11501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hematology Oncology Associates of Rockland, PC</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10956</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southeastern Medical Oncology Center</name>
      <address>
        <city>Goldsboro</city>
        <state>North Carolina</state>
        <zip>27534</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aultman Cancer Center</name>
      <address>
        <city>Canton</city>
        <state>Ohio</state>
        <zip>44710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Cleveland Clinic Foundation Hematology/Med Oncology</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Legacy Good Samaritan</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SCOA-SC Onc Assoc</name>
      <address>
        <city>Columbia</city>
        <state>South Carolina</state>
        <zip>29201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VA Department of Hematology/Oncology</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hope Oncology</name>
      <address>
        <city>Richardson</city>
        <state>Texas</state>
        <zip>75080</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Blood and Cancer Center of East Texas</name>
      <address>
        <city>Tyler</city>
        <state>Texas</state>
        <zip>75701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tyler Hematology/Oncology</name>
      <address>
        <city>Tyler</city>
        <state>Texas</state>
        <zip>75701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Veterans Administration Medical Center</name>
      <address>
        <city>White River Junction</city>
        <state>Vermont</state>
        <zip>05009</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Oncology Associates Research Program</name>
      <address>
        <city>Newport News</city>
        <state>Virginia</state>
        <zip>23606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Olympic Hematology/Oncology</name>
      <address>
        <city>Bremerton</city>
        <state>Washington</state>
        <zip>98310</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Morgantown Internal Medicine Group</name>
      <address>
        <city>Morgantown</city>
        <state>West Virginia</state>
        <zip>26505</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>September 7, 2005</study_first_submitted>
  <study_first_submitted_qc>September 7, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 12, 2005</study_first_posted>
  <results_first_submitted>March 19, 2019</results_first_submitted>
  <results_first_submitted_qc>September 4, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">September 6, 2019</results_first_posted>
  <last_update_submitted>September 4, 2019</last_update_submitted>
  <last_update_submitted_qc>September 4, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 6, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Erlotinib</keyword>
  <keyword>Tarceva</keyword>
  <keyword>Web based</keyword>
  <keyword>Stage III NSCLC</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Erlotinib Hydrochloride</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Period 1: 245 patients were registered &amp; randomized. Of those, 10 patients were ineligible due to incorrect stage, withdrawal of consent, inability to meet radiation therapy parameters, and inadequate functional status. The number of participants for each specific reason for ineligibility is unknown. They did not receive any study intervention.</recruitment_details>
      <pre_assignment_details>Period 2:Study drug dispensed to only chemoradiation patients who did not experience disease progression, consent withdrawal, death, investigators discretion, or toxicity.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Tarceva</title>
          <description>Tarceva 150mg
Erlotinib (tarceva): Erlotinib 150mg orally each day. Patients will be treated on a continuous, once daily oral dosing schedule until disease progression, withdrawal of consent, unacceptable adverse events, death or completion of 3 years of therapy.</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Matched Placebo
Placebo: Matched placebo orally each day. Patients will be treated on a continuous, once daily oral dosing schedule until disease progression, withdrawal of consent, unacceptable adverse events death or completion of 3 years of therapy.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Concurrent Chemoradiation</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="123"/>
                <participants group_id="P2" count="122"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received Chemoradiation</title>
              <participants_list>
                <participants group_id="P1" count="118"/>
                <participants group_id="P2" count="117"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="118"/>
                <participants group_id="P2" count="117"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Investigational Drug</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="118"/>
                <participants group_id="P2" count="117"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Investigational Drug Dispensed</title>
              <participants_list>
                <participants group_id="P1" count="77"/>
                <participants group_id="P2" count="75"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="77"/>
                <participants group_id="P2" count="75"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="41"/>
                <participants group_id="P2" count="42"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Tarceva</title>
          <description>Tarceva 150mg
Erlotinib (tarceva): Erlotinib 150mg orally each day. Patients will be treated on a continuous, once daily oral dosing schedule until disease progression, withdrawal of consent, unacceptable adverse events, death or completion of 3 years of therapy.</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Matched Placebo
Placebo: Matched placebo orally each day. Patients will be treated on a continuous, once daily oral dosing schedule until disease progression, withdrawal of consent, unacceptable adverse events death or completion of 3 years of therapy.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="123"/>
            <count group_id="B2" value="122"/>
            <count group_id="B3" value="245"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="68" lower_limit="39" upper_limit="89"/>
                    <measurement group_id="B2" value="67" lower_limit="38" upper_limit="84"/>
                    <measurement group_id="B3" value="67.5" lower_limit="38" upper_limit="89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="45"/>
                    <measurement group_id="B2" value="55"/>
                    <measurement group_id="B3" value="100"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="78"/>
                    <measurement group_id="B2" value="67"/>
                    <measurement group_id="B3" value="145"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="109"/>
                    <measurement group_id="B2" value="106"/>
                    <measurement group_id="B3" value="215"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Progression Free Survival</title>
        <description>Progression Free Survival is defined as time from randomization until documented disease progression or death from any cause. The Response Evaluation Criteria In Solid Tumors Criteria (RECIST 1.0) was used to determine disease progression. Irradiated target lesions were considered non-measurable disease. Symptomatic radiographic changes of irradiated non-measurable disease required pathologically confirmation or positive FDG-PET scan 6 months following completion of concurrent chemoradiation to be considered locoregional disease progression. Global deterioration of health status requiring discontinuation of treatment without objective evidence of progression was considered distant disease progression.</description>
        <time_frame>5 years</time_frame>
        <population>NA = not available; The data cannot be located/provided due to the PI leaving the institution.</population>
        <group_list>
          <group group_id="O1">
            <title>Tarceva</title>
            <description>Tarceva 150mg
Erlotinib (tarceva): Erlotinib 150mg orally each day. Patients will be treated on a continuous, once daily oral dosing schedule until disease progression, withdrawal of consent, unacceptable adverse events, death or completion of 3 years of therapy.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matched Placebo
Placebo: Matched placebo orally each day. Patients will be treated on a continuous, once daily oral dosing schedule until disease progression, withdrawal of consent, unacceptable adverse events death or completion of 3 years of therapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Progression Free Survival</title>
          <description>Progression Free Survival is defined as time from randomization until documented disease progression or death from any cause. The Response Evaluation Criteria In Solid Tumors Criteria (RECIST 1.0) was used to determine disease progression. Irradiated target lesions were considered non-measurable disease. Symptomatic radiographic changes of irradiated non-measurable disease required pathologically confirmation or positive FDG-PET scan 6 months following completion of concurrent chemoradiation to be considered locoregional disease progression. Global deterioration of health status requiring discontinuation of treatment without objective evidence of progression was considered distant disease progression.</description>
          <population>NA = not available; The data cannot be located/provided due to the PI leaving the institution.</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="118"/>
                <count group_id="O2" value="117"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.4" lower_limit="NA" upper_limit="NA">Data could not be found; The data cannot be located/provided due to the PI leaving the institution.</measurement>
                    <measurement group_id="O2" value="8.1" lower_limit="NA" upper_limit="NA">Data could not be found; The data cannot be located/provided due to the PI leaving the institution.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.165</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.93</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.65</ci_lower_limit>
            <ci_upper_limit>1.33</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival</title>
        <time_frame>From date of randomization until the date of death from any cause, assessed up to 50 months</time_frame>
        <population>NA = not available; The data cannot be located/provided due to the PI leaving the institution.</population>
        <group_list>
          <group group_id="O1">
            <title>Tarceva</title>
            <description>Tarceva 150mg
Erlotinib (tarceva): Erlotinib 150mg orally each day. Patients will be treated on a continuous, once daily oral dosing schedule until disease progression, withdrawal of consent, unacceptable adverse events, death or completion of 2 years of therapy.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matched Placebo
Placebo: Matched placebo orally each day. Patients will be treated on a continuous, once daily oral dosing schedule until disease progression, withdrawal of consent, unacceptable adverse events death or completion of 3 years of therapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival</title>
          <population>NA = not available; The data cannot be located/provided due to the PI leaving the institution.</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="118"/>
                <count group_id="O2" value="117"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.5" lower_limit="NA" upper_limit="NA">Data could not be found; The data cannot be located/provided due to the PI leaving the institution.</measurement>
                    <measurement group_id="O2" value="20.3" lower_limit="NA" upper_limit="NA">Data could not be found; The data cannot be located/provided due to the PI leaving the institution.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.32</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.18</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.85</ci_lower_limit>
            <ci_upper_limit>1.63</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent of Participants Surviving 3 Years</title>
        <time_frame>36 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Tarceva</title>
            <description>Tarceva 150mg
Erlotinib (tarceva): Erlotinib 150mg orally each day. Patients will be treated on a continuous, once daily oral dosing schedule until disease progression, withdrawal of consent, unacceptable adverse events, death or completion of 3 years of therapy.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matched Placebo
Placebo: Matched placebo orally each day. Patients will be treated on a continuous, once daily oral dosing schedule until disease progression, withdrawal of consent, unacceptable adverse events death or completion of 3 years of therapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Participants Surviving 3 Years</title>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="118"/>
                <count group_id="O2" value="117"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37"/>
                    <measurement group_id="O2" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serious Adverse Event Profile Relating to Death, Disability, Life-threatening, Hospitalization, and Impairment/Damage for Concurrent Chemoradiation</title>
        <description>Number of participants with treatment-related serious adverse events (SAEs) observed in each SAE category for each arm relating to death, disability, life-threatening, hospitalization, and impairment/damage is reported. For participants with multiple SAEs, the SAE report having the strongest relationship to study drug is summarized.</description>
        <time_frame>18 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Tarceva</title>
            <description>Tarceva 150mg
Erlotinib (tarceva): Erlotinib 150mg orally each day. Patients will be treated on a continuous, once daily oral dosing schedule until disease progression, withdrawal of consent, unacceptable adverse events, death or completion of 3 years of therapy.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matched Placebo
Placebo: Matched placebo orally each day. Patients will be treated on a continuous, once daily oral dosing schedule until disease progression, withdrawal of consent, unacceptable adverse events death or completion of 3 years of therapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Serious Adverse Event Profile Relating to Death, Disability, Life-threatening, Hospitalization, and Impairment/Damage for Concurrent Chemoradiation</title>
          <description>Number of participants with treatment-related serious adverse events (SAEs) observed in each SAE category for each arm relating to death, disability, life-threatening, hospitalization, and impairment/damage is reported. For participants with multiple SAEs, the SAE report having the strongest relationship to study drug is summarized.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="118"/>
                <count group_id="O2" value="117"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Death</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Disability</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Life-threatening</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hospitalization</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                    <measurement group_id="O2" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Impairment/damange</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serious Adverse Event Profile Relating to Death, Disability, Life-threatening, Hospitalization, and Impairment/Damage for Erlotinib and Placebo</title>
        <description>Number of participants with treatment-related serious adverse events (SAEs) observed in each SAE category for each arm relating to death, disability, life-threatening, hospitalization, and impairment/damage is reported. For participants with multiple SAEs, the SAE report having the strongest relationship to study drug is summarized.</description>
        <time_frame>18 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Tarceva</title>
            <description>Tarceva 150mg
Erlotinib (tarceva): Erlotinib 150mg orally each day. Patients will be treated on a continuous, once daily oral dosing schedule until disease progression, withdrawal of consent, unacceptable adverse events, death or completion of 3 years of therapy.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matched Placebo
Placebo: Matched placebo orally each day. Patients will be treated on a continuous, once daily oral dosing schedule until disease progression, withdrawal of consent, unacceptable adverse events death or completion of 3 years of therapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Serious Adverse Event Profile Relating to Death, Disability, Life-threatening, Hospitalization, and Impairment/Damage for Erlotinib and Placebo</title>
          <description>Number of participants with treatment-related serious adverse events (SAEs) observed in each SAE category for each arm relating to death, disability, life-threatening, hospitalization, and impairment/damage is reported. For participants with multiple SAEs, the SAE report having the strongest relationship to study drug is summarized.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="77"/>
                <count group_id="O2" value="75"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Death</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Disability</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Life-threatening</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hospitalization (initial or prolonged)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                    <measurement group_id="O2" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Impairment/damange</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>The intent-to-treat population included 235 eligible randomized patients to the erlotinib arm (n = 118) or placebo arm (n = 117); 245 randomized, 10 became ineligible prior to any treatment. Patients were evaluated with a medical history, physical exam, laboratory studies, and toxicity assessment starting at 1st dose, every 4 weeks for 2 months, then every 8-12 weeks until treatment discontinuation. Participants were evaluated, on average, for 6 months, and through study completion up to 3 years</time_frame>
      <desc>Common Toxicities are reported. Adverse events (Serious, Other Adverse Events) are reporting for only those participants who are included in the intent-to-treat population .This study used the National Cancer Institute Common Toxicity Criteria (NCI-CTC) version 3.0 for grading and reporting of toxicities and adverse events.</desc>
      <group_list>
        <group group_id="E1">
          <title>Chemoradiation Before Tarceva</title>
        </group>
        <group group_id="E2">
          <title>Chemoradiation Before Placebo</title>
        </group>
        <group group_id="E3">
          <title>Tarceva</title>
          <description>Tarceva 150mg
Erlotinib (tarceva): Erlotinib 150mg orally each day. Patients will be treated on a continuous, once daily oral dosing schedule until disease progression, withdrawal of consent, unacceptable adverse events, death or completion of 3 years of therapy.</description>
        </group>
        <group group_id="E4">
          <title>Placebo</title>
          <description>Matched Placebo
Placebo: Matched placebo orally each day. Patients will be treated on a continuous, once daily oral dosing schedule until disease progression, withdrawal of consent, unacceptable adverse events death or completion of 3 years of therapy.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="118"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="117"/>
                <counts group_id="E3" subjects_affected="43" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="40" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="118"/>
                <counts group_id="E2" subjects_affected="38" subjects_at_risk="117"/>
                <counts group_id="E3" subjects_affected="39" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="23" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Hemoglobin</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <description>Supraventricular and nodal arrhythmia</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="118"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="117"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Cardiac Arrhythmia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="118"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Cardiac General</sub_title>
                <description>Cardiac General</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="117"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="77"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Cardiac ischemia/infarction</sub_title>
                <description>Cardiac ischemia/infarction</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="117"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="117"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Paroxysmal Atrial Tachycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Ventricular fibrillation</sub_title>
                <description>Ventricular arrhythmia</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="117"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="118"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="117"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Dysphagia (difficulty swallowing)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="117"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Esophagitis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="118"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="117"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Fistula, Esophagus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <description>Gastritis (including bile reflux gastritis)</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="117"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Gastrointestinal - Other</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="118"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Mucositis/stomatitis</sub_title>
                <description>Mucositis/stomatitis (functional/symptomatic) Esophagus</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="117"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Perforation, GIColon</sub_title>
                <description>GI/Colon Perforation</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="117"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="118"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Constitutional Symptoms - Fatigue</sub_title>
                <description>Fatigue (asthenia, lethargy, malaise)</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="118"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Constitutional Symptoms - Fever</sub_title>
                <description>Fever (in the absence of neutropenia, where neutropenia is defined as ANC &lt;1.0 x 10eFever (in the absence of neutropenia, where neutropenia is defined as ANC &lt;1.0 x 10e9/L)9/L)</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="117"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Constitutional Symptoms- Other</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="118"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Hemorrhage - Respiratory tract NOS</sub_title>
                <description>Hemorrhage, pulmonary/upper respiratory/ Respiratory tract None otherwise specified (NOS)</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Hemorrhage, GI Lower</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="117"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Hemorrhage, pulmonary/upper respiratory - Bronchopulmonary</sub_title>
                <description>Hemorrhage, pulmonary/upper respiratory Bronchopulmonary</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="117"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Hemorrhage, pulmonary/upper respiratory- Lung</sub_title>
                <description>Hemorrhage, pulmonary/upper respiratory- Lung</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="118"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Hemorrhage/Bleeding - Other</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="118"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Pain - Abdomen NOS</sub_title>
                <description>None otherwise specified (NOW)</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Pain - Bone</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="77"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Pain - Joint</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="118"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Pain - Other</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="77"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Pain- Chest/thorax</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="117"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic Reaction</sub_title>
                <description>Allergic reaction/hypersensitivity (including drug fever)</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="118"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="117"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Colitis, Infectious</sub_title>
                <description>example: Clostridium difficile</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <description>Febrile neutropenia (fever of unknown origin without clinically or microbiologically documented infection)(ANC &lt;1.0 x 10e9/L, fever &gt;=38.5 degrees C)</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="118"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Infection - Blood</sub_title>
                <description>Infection with normal ANC or Grade 1 or 2 neutrophils Blood</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="118"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Infection - Foreign body</sub_title>
                <description>Infection with normal ANC or Grade 1 or 2 neutrophils Foreign body (e.g., graft, implant, prosthesis, stent)</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="118"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="77"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Infection - Lung</sub_title>
                <description>Infection with normal ANC or Grade 1 or 2 neutrophils Lung (pneumonia)</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="118"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="77"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Infection - Other</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="118"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="117"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="77"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Infection - Wound</sub_title>
                <description>Infection with normal ANC or Grade 1 or 2 neutrophils Wound</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="117"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="117"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="117"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Musculoskeletal / Soft Tissue - Other</sub_title>
                <description>Musculoskeletal / Soft Tissue - Other</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebrovascular Ischemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="117"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Confusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="118"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="117"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Neurology - Other</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Somnolence/depressed level of consciousness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="118"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Obstruction - Ureter</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnea (shortness of breath)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="117"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="77"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="117"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Pleural effusion (non-malignant)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Pneumonitis/pulmonary infiltrates</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="118"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="117"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="77"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Upper Respiratory - Other</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="118"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="117"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="77"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin - Other</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="118"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Wound complication, non-infectious</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="117"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Intra-operative Injury - Other</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Thrombosis/embolism (vascular access-related)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="118"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Thrombosis/thrombus/embolism</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="118"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="117"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="77"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Vascular - Other</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="118"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="118"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="117"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Hemoglobin</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="118"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="117"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <description>Supraventricular and nodal arrhythmia Atrial fibrillation</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="117"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Cardiac General - Other</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="118"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="118"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="117"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Esophagitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="118"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Gastrointestinal - Other</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="118"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="118"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Constitutional symptoms - Fever</sub_title>
                <description>Fever (in the absence of neutropenia, where neutropenia is defined as ANC &lt;1.0 x 10e9/L)</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="118"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Pain - Chest/Thorax</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="118"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Pain - Other</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="118"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Pain - Abdomen NOS</sub_title>
                <description>None otherwise specified (NOS)</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic reaction</sub_title>
                <description>Allergic reaction/hypersensitivity (including drug fever)</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="118"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection - Other</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="117"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="117"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Extrapyramidal/involuntary movement/restlessness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="117"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pneumonitis/pulmonary infiltrates</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="117"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="118"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Upper respiratory - other</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin - Other</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="117"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Desquamation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Embolism</sub_title>
                <description>Thrombosis/ thrombus/ embolism</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Clinical Research Office</name_or_title>
      <organization>Dartmouth-Hitchcock Medical Center</organization>
      <email>Cancer.Research.Nurse@Dartmouth.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

